MX2021006243A - Composiciones sinergicas que comprenden (r)-2-(2-oxopirrolidin-1-i l)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporcion no racemica. - Google Patents

Composiciones sinergicas que comprenden (r)-2-(2-oxopirrolidin-1-i l)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporcion no racemica.

Info

Publication number
MX2021006243A
MX2021006243A MX2021006243A MX2021006243A MX2021006243A MX 2021006243 A MX2021006243 A MX 2021006243A MX 2021006243 A MX2021006243 A MX 2021006243A MX 2021006243 A MX2021006243 A MX 2021006243A MX 2021006243 A MX2021006243 A MX 2021006243A
Authority
MX
Mexico
Prior art keywords
oxopyrrolidin
butanamide
utanamide
composition
synergistic compositions
Prior art date
Application number
MX2021006243A
Other languages
English (en)
Inventor
Michael Scherz
Carlo Farina
Carla Ghelardini
Cesare Mannelli Lorenzo Di
Original Assignee
Metys Pharmaceuticals AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metys Pharmaceuticals AG filed Critical Metys Pharmaceuticals AG
Publication of MX2021006243A publication Critical patent/MX2021006243A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se refiere a una composición de los enantiómeros de 2-(2-oxopirrolidin-1-il)butanamida y solvatos o co-cristales farmacéuticamente aceptables de la misma en una cierta proporción, una composición farmacéutica que comprende dicha composición, su uso como un medicamento y el uso de las composiciones o composiciones farmacéuticas inventivas en el tratamiento y/o prevención de una enfermedad o trastorno seleccionado generalmente y preferiblemente de trastornos relacionados con las convulsiones, neuropatía sensorial periférica, preferiblemente dolor neuropático periférico; convulsiones; depresión; o deterioro cognitivo.
MX2021006243A 2018-12-04 2019-12-04 Composiciones sinergicas que comprenden (r)-2-(2-oxopirrolidin-1-i l)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporcion no racemica. MX2021006243A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18210106 2018-12-04
PCT/EP2019/083594 WO2020115093A1 (en) 2018-12-04 2019-12-04 Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio

Publications (1)

Publication Number Publication Date
MX2021006243A true MX2021006243A (es) 2021-08-11

Family

ID=64604549

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006243A MX2021006243A (es) 2018-12-04 2019-12-04 Composiciones sinergicas que comprenden (r)-2-(2-oxopirrolidin-1-i l)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporcion no racemica.

Country Status (20)

Country Link
US (1) US20220047548A1 (es)
EP (1) EP3890833B1 (es)
JP (1) JP2022510363A (es)
KR (1) KR20210099567A (es)
CN (1) CN113164767A (es)
AU (1) AU2019391309A1 (es)
BR (1) BR112021010739A2 (es)
CA (1) CA3117350A1 (es)
CO (1) CO2021007055A2 (es)
EA (1) EA202191485A1 (es)
EC (1) ECSP21040300A (es)
ES (1) ES2953785T3 (es)
HU (1) HUE062575T2 (es)
IL (1) IL283441A (es)
JO (1) JOP20210082A1 (es)
MX (1) MX2021006243A (es)
PL (1) PL3890833T3 (es)
SG (1) SG11202105863PA (es)
WO (1) WO2020115093A1 (es)
ZA (1) ZA202102701B (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
EP1034826A1 (en) 1999-03-05 2000-09-13 Reuter Chemische Apparatebau Co-crystallization process
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
ITMI20030573A1 (it) 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
CA2488325C (en) * 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
CA2657571A1 (en) * 2006-07-25 2008-01-31 Zach System S.P.A. Process for the preparation of levetiracetam
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
EP2098526B1 (en) 2008-02-22 2014-01-15 Neurotune AG Nitrogen-containing bicyclic compounds active on chronic pain conditions
EP2671858A1 (en) * 2012-06-08 2013-12-11 Université Catholique De Louvain Process for chiral resolution of etiracetam
JOP20190251A1 (ar) * 2017-05-31 2019-10-21 Metys Pharmaceuticals AG تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية

Also Published As

Publication number Publication date
HUE062575T2 (hu) 2023-11-28
CN113164767A (zh) 2021-07-23
EA202191485A1 (ru) 2021-08-30
KR20210099567A (ko) 2021-08-12
SG11202105863PA (en) 2021-07-29
EP3890833B1 (en) 2023-06-07
IL283441A (en) 2021-07-29
PL3890833T3 (pl) 2023-09-18
EP3890833C0 (en) 2023-06-07
AU2019391309A1 (en) 2021-05-20
BR112021010739A2 (pt) 2021-08-24
ECSP21040300A (es) 2021-07-30
WO2020115093A1 (en) 2020-06-11
ZA202102701B (en) 2023-10-25
CO2021007055A2 (es) 2021-06-10
US20220047548A1 (en) 2022-02-17
JOP20210082A1 (ar) 2023-01-30
EP3890833A1 (en) 2021-10-13
CA3117350A1 (en) 2020-06-11
ES2953785T3 (es) 2023-11-16
JP2022510363A (ja) 2022-01-26

Similar Documents

Publication Publication Date Title
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
MX2022001874A (es) Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos.
MY189740A (en) Butylphthalide-telmisartan heterocomplex, preparation method and application thereof
MX2023009685A (es) Inhibidores de tyk2 y sus usos.
PH12018500859A1 (en) Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease
EP4028021C0 (fr) Utilisation de nmn pour la prévention et/ou le traitement de la douleur et compositions correspondantes
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
PH12019502580A1 (en) Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio
GEP20247644B (en) Inhibitors of adrenoreceptor adrac2
MX2021007142A (es) Compuestos organicos.
MX2023009613A (es) Terapia combinada de obicetrapib y ezetimiba para usarse en pacientes intolerantes a las estatinas que sufren hiperlipidemia o dislipidemia mixta.
ZA202102701B (en) Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio
SG11202106163RA (en) Pharmaceutical composition for prevention or treatment of cancer comprising lactobacillus sakei wikim30 as active ingredient
PH12021551239A1 (en) Synergistic compositions comprising r-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones and s-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones in a non-racemic ratio
MX2020000834A (es) Derivado de adamantilmetilamina y uso del mismo como producto farmaceutico.
MX2019013717A (es) Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia.
ZA202110478B (en) Immediate release fixed-dose combination of memantine and donepezil
MX2022001159A (es) Nueva formulacion farmaceutica.
MX2023010542A (es) Uso de mevidaleno y otros moduladores alostéricos positivos d1 para ralentizar la progresión de la enfermedad de parkinson.
MX2022000373A (es) Combinacion de ibuprofeno y tramadol para aliviar el dolor.
ZA202104167B (en) Compounds for use in the treatment of parkinson's disease
WO2021119327A3 (en) Transpore delivery of cannabinoid and uses thereof
MX2022001023A (es) Compuestos de aminotiolester y usos de los mismos.
EA201791798A1 (ru) Фармацевтические композиции, включающие n-(3,5-диметоксифенил)-n'-(1-метилэтил)-n-[3-(1-метил-1h-пиразол-4-ил)хиноксалин-6-ил]этан-1,2-диамин